EA201391012A1 - Лиганды, связывающиеся с рецепторами tgf-бета типа ii - Google Patents

Лиганды, связывающиеся с рецепторами tgf-бета типа ii

Info

Publication number
EA201391012A1
EA201391012A1 EA201391012A EA201391012A EA201391012A1 EA 201391012 A1 EA201391012 A1 EA 201391012A1 EA 201391012 A EA201391012 A EA 201391012A EA 201391012 A EA201391012 A EA 201391012A EA 201391012 A1 EA201391012 A1 EA 201391012A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fibrosis
tgfβrii
amino acid
variable domain
accordingly
Prior art date
Application number
EA201391012A
Other languages
English (en)
Russian (ru)
Inventor
Эндрю Битон
Кэролайн Димеч
Питер Франц Эртл
Сюзанна Карен Форд
Рут Макадам
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45444622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA201391012A1 publication Critical patent/EA201391012A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
EA201391012A 2011-01-06 2012-01-04 Лиганды, связывающиеся с рецепторами tgf-бета типа ii EA201391012A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161430235P 2011-01-06 2011-01-06
PCT/EP2012/050061 WO2012093125A1 (en) 2011-01-06 2012-01-04 Ligands that bind tgf-beta receptor ii

Publications (1)

Publication Number Publication Date
EA201391012A1 true EA201391012A1 (ru) 2014-01-30

Family

ID=45444622

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391012A EA201391012A1 (ru) 2011-01-06 2012-01-04 Лиганды, связывающиеся с рецепторами tgf-бета типа ii

Country Status (22)

Country Link
US (3) US9150651B2 (https=)
EP (1) EP2661449B1 (https=)
JP (2) JP6062375B2 (https=)
KR (1) KR101886898B1 (https=)
CN (1) CN103443126B (https=)
AU (1) AU2016203609A1 (https=)
BR (1) BR112013016917A2 (https=)
CA (1) CA2823104A1 (https=)
CL (1) CL2013001975A1 (https=)
CO (1) CO6811807A2 (https=)
CR (1) CR20130376A (https=)
DO (1) DOP2013000162A (https=)
EA (1) EA201391012A1 (https=)
ES (1) ES2627299T3 (https=)
IL (1) IL227254A0 (https=)
MA (1) MA34820B1 (https=)
MX (1) MX2013007936A (https=)
PE (1) PE20140982A1 (https=)
PH (1) PH12013501397A1 (https=)
SG (1) SG191762A1 (https=)
WO (1) WO2012093125A1 (https=)
ZA (1) ZA201304726B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
JP6062375B2 (ja) * 2011-01-06 2017-01-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド
DK2723769T4 (da) * 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
CN105143258B (zh) * 2013-03-15 2020-06-23 Ac免疫有限公司 抗Tau抗体和使用方法
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
WO2015077540A2 (en) * 2013-11-21 2015-05-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
EP3094649A1 (en) * 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding properties
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
CN106794233B (zh) * 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
WO2017041114A2 (en) * 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CN115925919A (zh) * 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
CN108883181A (zh) * 2016-04-05 2018-11-23 葛兰素史密斯克莱知识产权发展有限公司 在免疫疗法中抑制TGFβ
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
GB201807693D0 (en) * 2018-05-11 2018-06-27 Autolus Ltd Cell
JP7542799B2 (ja) * 2018-07-04 2024-09-02 京都府公立大学法人 眼組織の線維化抑制用組成物
CN114173806A (zh) * 2019-07-26 2022-03-11 密歇根州立大学董事会 预防或治疗骨骼肌脂肪变性的方法
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
EP4291227A2 (en) 2021-02-15 2023-12-20 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
PL1737962T3 (pl) 2004-03-24 2011-02-28 Domantis Ltd Uniwersalny lider GAS1
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
US20070012251A1 (en) 2005-07-07 2007-01-18 Martin Zucker Seal arrangement with corrosion barrier and method
JP2009523460A (ja) 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
BR112012001977A2 (pt) 2009-07-29 2017-01-31 Glaxo Group Ltd domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar.
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
JP6062375B2 (ja) * 2011-01-06 2017-01-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド

Also Published As

Publication number Publication date
CR20130376A (es) 2013-11-29
JP6062375B2 (ja) 2017-01-18
DOP2013000162A (es) 2014-01-15
ES2627299T3 (es) 2017-07-27
NZ612839A (en) 2014-09-26
AU2012204867B2 (en) 2016-03-10
MX2013007936A (es) 2013-08-09
CL2013001975A1 (es) 2014-03-07
CA2823104A1 (en) 2012-07-12
AU2016203609A1 (en) 2016-06-16
JP2017051191A (ja) 2017-03-16
SG191762A1 (en) 2013-08-30
US20130302335A1 (en) 2013-11-14
EP2661449A1 (en) 2013-11-13
ZA201304726B (en) 2014-03-26
AU2012204867A8 (en) 2016-03-24
US20180086835A1 (en) 2018-03-29
KR20140036146A (ko) 2014-03-25
WO2012093125A1 (en) 2012-07-12
JP2014504866A (ja) 2014-02-27
US9150651B2 (en) 2015-10-06
US9850307B2 (en) 2017-12-26
JP6453289B2 (ja) 2019-01-16
US20150361176A1 (en) 2015-12-17
EP2661449B1 (en) 2017-03-22
AU2012204867A1 (en) 2013-07-25
IL227254A0 (en) 2013-09-30
PH12013501397A1 (en) 2013-08-28
CN103443126B (zh) 2016-11-23
KR101886898B1 (ko) 2018-08-08
CN103443126A (zh) 2013-12-11
BR112013016917A2 (pt) 2017-04-04
MA34820B1 (fr) 2014-01-02
CO6811807A2 (es) 2013-12-16
PE20140982A1 (es) 2014-08-22

Similar Documents

Publication Publication Date Title
EA201391012A1 (ru) Лиганды, связывающиеся с рецепторами tgf-бета типа ii
HRP20210777T1 (hr) Pripravci protiv cgrp-a njihova upotreba
JP2014504866A5 (https=)
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
JP2012529436A5 (https=)
EP2174668A3 (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
RU2014111472A (ru) Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1
EA201000018A1 (ru) Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения
BR112015012366A2 (pt) antagonistas de cxcr7
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
WO2006110214A3 (en) Antibodies against mammalian metapneumovirus
JP2012505912A5 (https=)
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
RU2011110169A (ru) Антитела против ccr2
RU2011141522A (ru) Антиангиогенные слитые белки
MX2012008780A (es) Metodos y composiciones que usan polipeptidos de fusion de fgf23.
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EP3345925A3 (en) Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
EA201290028A1 (ru) Однодоменные антитела против рецептора tgf-бета ii типа
NZ623576A (en) Tfpi inhibitors and methods of use
EA201391548A1 (ru) Иммуногенная композиция
NZ599114A (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2009089062A8 (en) Cadherin-11 ec1 domain antagonists for treating inflammatory joint disorders